WHO approves first mpox diagnostic test for emergency use
Health & Science
By
Xinhua
| Oct 04, 2024
The World Health Organization (WHO) said on Friday that it has approved the first diagnostic test for mpox, marking a significant milestone in expanding global access to mpox testing.
The approval comes as Africa continues to struggle with limited testing capacity, which fueled the spread of the virus. Over 30,000 suspected mpox cases have been reported across the continent in 2024, with the Democratic Republic of the Congo (DRC), Burundi, and Nigeria being the most affected.
In the DRC, only 37 per cent of suspected cases have been tested this year, according to the global health agency.
The test, known as Alinity m MPXV assay, will boost diagnostic capacity in countries facing mpox outbreaks, where rapid and accurate testing is crucial.
READ MORE
Why every Kenyan must protect their personal data
Konza inks deal with Moroccan firm to deliver AI certification
AG's office in the spot for hindering KenGen's cheaper power plan
Pesalink, PAPSS deal cuts currency barriers for Kenya cross-border payments
Manyanja Mall: Quickmart, Goodlife and Rubis among anchor tenants of Sh400 million mall
Econetix inaugural CORSIA deal channels carbon finance to Africa
Industry leaders push to accelerate social governance in brokerage
VAT reforms: Why manufacturers want tax cuts
The Alinity m MPXV assay is a real-time PCR test designed to detect mpox virus DNA from human skin lesion swabs, enabling laboratory and health workers to confirm cases quickly.
"This first mpox diagnostic test listed under the Emergency Use Listing procedure represents a significant milestone in expanding testing availability in affected countries," said Yukiko Nakatani, WHO's assistant director-general for access to medicines and health products.